bluebird bio (BLUE) Set to Announce Earnings on Thursday

bluebird bio (NASDAQ:BLUE) will be posting its quarterly earnings results before the market opens on Thursday, May 9th. Analysts expect bluebird bio to post earnings of ($0.47) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

bluebird bio Stock Up 1.0 %

Shares of BLUE stock opened at $1.01 on Wednesday. bluebird bio has a 52-week low of $0.85 and a 52-week high of $5.53. The stock’s 50-day moving average price is $1.21 and its 200 day moving average price is $1.87. The stock has a market capitalization of $110.43 million, a PE ratio of -1.36 and a beta of 0.82.

Analysts Set New Price Targets

Several brokerages recently weighed in on BLUE. StockNews.com raised bluebird bio to a “sell” rating in a report on Thursday, March 28th. William Blair restated a “market perform” rating on shares of bluebird bio in a research note on Tuesday, January 9th. Wells Fargo & Company dropped their price target on shares of bluebird bio from $4.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Wednesday, March 27th. HSBC reduced their price objective on shares of bluebird bio from $2.31 to $1.02 and set a “reduce” rating for the company in a research report on Tuesday, March 5th. Finally, Wedbush dropped their target price on bluebird bio from $1.72 to $1.68 and set a “neutral” rating on the stock in a research report on Tuesday, March 19th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $5.74.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.